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OBJECTIVES: To measure the efﬁciency of pharmacy resources
utilization in ﬁve Primary Care centres by the retrospective appli-
cation of Adjusted Clinical Groups (ACG) in a usual clinical
practice setting. METHODS: Retrospective study carried out on
the basis of the clinical records from all the attended patients
along the year 2006. Main variables: age, sex, case-mix/episodes,
visits, pharmacy costs, centre, physician and service (Family
Medicine or Pediatrics). ACG grouper (Starﬁeld and Weiner,
Johns Hopkins University, n = 106) classiﬁes each patient in a
unique category of similar resource consumption. A Receiver
Operating Characteristics (ROC-area under the curve) analysis
was done to assess the predictive value of the model. The
Efﬁciency Index (EI) was obtained as the quotient between the
observed and the expected pharmacy costs according to ACG
distribution (indirect standardization). The statistical package
SPSS was used (p < 0.05). RESULTS: A total of 80,775 patients
were included. Average number of episodes 4.83.5 and visits
7.98.2; mean age: 40.722.9 years; and 46.9% of males.
Intensity of utilization: 72.4%. Costs of drug prescription:
€22.7 millions (55.6% of the total costs). Mean cost was
€281.05627.85. ROC curve analysis for episodes: 0.588
(p = 0.000); sensibility: 37.3%, speciﬁcity: 73.1% and intra-class
correlation coefﬁcient C: 0.732 (p < 0.001). The EI for each
centre was respectively: 0.91 (CI: 0.78–1.04), 0.93 (CI: 0.77–
1.09), 0.96 (CI: 0.81–1.11), 1.06 (CI: 0.95–1.17) and 1.07 (CI:
0.95–1.19), p < 0.0001. Furthermore, differences between family
physicians and pediatricians were observed (range: 0.55–1.46),
p < 0.0001. CONCLUSION: Results show a wide variability in
the costs of pharmacy within centres and physicians. ACG
provide an adjusted approximation to efﬁciency in pharmacy
costs. Efﬁciency must not be considered as an isolated dimension
of quality. The determination of the El could lead to a better
knowledge of the prescription proﬁle from individual physicians
and/or primary care teams.
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OBJECTIVES: To evaluate the impact of RDUR pharmacist’s
interventions on physician prescribing and the level of spill over
effect on future prescriptions following the intervention.
METHODS: A retrospective case-control study was conducted
at a Pharmacy Beneﬁt Manager using the available prescription
data during April 2004 to August 2005. Pharmacy claims for two
populations were run through the PBM’s rules engine to identify
conﬂicts. RDUR conﬂicts evaluated and intervened by a clinical
pharmacist served as a case group whereas conﬂicts that were not
evaluated and intervened by a clinical pharmacist served as a
control group. The interventional spill over effect evaluates the
rate of repetitive interventions that occur based on the total
number of non-repetitive interventions. RESULTS: A total of
40,284 conﬂicts were identiﬁed in the case group and 13,044
conﬂicts in the control group. For cases, 32,780 interventions
were considered non-repetitive and 529 were repetitive. There
were 22,870 physicians in cases that received intervention letters
and 2348 physicians in the control group that would have been
received intervention letters during the study period. Each phy-
sician received on average 1.4 interventions for cases versus 3.0
in controls. Among the case physicians who were intervened
during the study period, 2.2% (505) were involved in a repeated
intervention versus 18.2% (428) in controls (p < 0.001), which is
an eight fold difference. The most common conﬂict intervened on
in cases was therapeutic appropriateness (8277, 25.3%) and for
controls it was drug-drug interactions (1796, 25.4%). The inter-
ventional spill over effect in cases was 98.4% versus 89.4% in
controls (p = 0.01). CONCLUSION: RDUR is an effective
interventional program which results in decreased number of
interventions per physician and provides a signiﬁcant impact on
future prescribing habits.
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OBJECTIVES: To identify the amount of medicines wasted in the
Portuguese National Health System and related direct ﬁnancial
costs. METHODS: A community-pharmacy based study used
two structured questionnaires to collect patient data at baseline
and after a follow-up period. The ﬁrst, administered by a phar-
macist to ﬁrst time users of any oral drug, intended to identify the
length of prescribed treatment, posology and size of medicines
packs. The second, developed for telephone interview and
applied after the predicted length of treatment or at the end of the
package (for chronic therapies). The total waste was related to:
1) inadequacy of medicines package sizes, or 2) lack of adherence
to the prescribed treatment. SAS version 8.2 package was used.
The average amount of wastage, was quantiﬁed and the 95%
conﬁdence intervals. A simulation study determined which
package sizes would minimize the wastage due to prescription of
inadequate package sizes. RESULTS: From September 2005 to
2006, 1601 patients with a mean age of 50 years were recruited.
68.6% were women. 2.098 Rx medicines were dispensed. An
average of 21.7% of waste per pack [20.3%–23.2%] was
identiﬁed. 9.7% was due to the inadequacy of drug pack sizes.
The average wastage cost per medicine dispensed was 4.44 €
[4.02 €-4.86 €], with 60.1% supported by the Portuguese
National Health System. The simulation study showed that the
wastage associated with the combination of Amoxicillin and
Clavulanic Acid could be reduced by 1.3 pills per pack, on
average, to 0.1 pills per pack, if a 12 units pack was available.
CONCLUSION: Medicines waste due to inadequacy of pack
sizes according to the proposed length of treatments was
identiﬁed, with a simulation study showing that this could be
minimized. Financial impact on the PNHS pharmaceutical
expenditure seems to be relevant, deserving further attention
and study.
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